CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 95 enrolled
Drug / intervention
Daclatasvir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00546715
NCT00546715Phase 2Completed
CompareCT.gov

Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

Bristol-Myers Squibb·interventional·Posted Oct 19, 2007·Updated Nov 18, 2015

In Brief

A Phase 2 clinical trial evaluating Daclatasvir and Placebo for Chronic Hepatitis C. Completed, enrolled 95 participants across 7 sites.

Detailed Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2007
Enrollment StartNov 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.7 years ago

Interventions

Daclatasvirdrug

Oral Solution, Oral, Single Dose

Placebodrug

Oral Solution, Oral, Single Dose